UPDATED: ARCH-backed Resilience nabs its latest financing round, putting together a massive $625M Series D
Since emerging from stealth in late 2020, Resilience has methodically built up its cash reserves and inked numerous collaboration deals. On Monday, the company announced its latest move.
The Bob Nelsen-backed biotech revealed plans for its Series D early Monday morning, putting together $625 million to further its mission of becoming the “Foxconn” of biotech. Monday’s new cash will be used to continue investing in its infrastructure through more deals, potential acquisitions and R&D expansion.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 144,900+ biopharma pros reading Endpoints daily — and it's free.